HeartBeam Inc. (NASDAQ: BEAT) reported second-quarter 2026 financial and operational results, highlighting significant progress across its heart attack detection program, 12-lead ECG extended wear patch, and initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026, and surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study. These milestones underscore the company's commitment to advancing the detection of acute coronary syndrome.
In addition to clinical progress, HeartBeam completed a working prototype of its 12-lead ECG extended wear patch, a key step toward a wearable device that can continuously monitor cardiac signals. The company has also signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients, marking the beginning of its commercial footprint. This early commercial traction is crucial as the company moves from development to market.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, compared with a net loss of $5 million, or $0.15 per share, in the same period a year earlier. Cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026. The company expects full-year 2026 net operating cash outflow to be below $14 million, which, combined with its current cash position, extends its cash runway into 2027. This financial prudence provides the company with the resources needed to achieve key clinical and commercial milestones.
The implications of these developments are significant. HeartBeam's technology, which synthesizes 3D ECG signals into a 12-lead ECG, has received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis software. The ongoing trials, ALIGN-ACS and HEADSTART-ACS, are designed to validate the technology's ability to detect heart attacks, potentially enabling earlier intervention and improved patient outcomes. The successful completion of these trials could position HeartBeam as a leader in portable cardiac monitoring.
Moreover, the early commercial agreements and product shipments indicate that the company is transitioning from a research-focused entity to a commercial-stage medical technology company. This shift is vital for generating revenue and achieving long-term sustainability. The extension of cash runway into 2027 provides the financial stability needed to navigate the regulatory and market adoption processes without immediate capital constraints.
Investors and healthcare professionals will be watching the presentation of ALIGN-ACS results at TCT 2026, a major cardiology conference, as well as the continued enrollment in HEADSTART-ACS. Positive data from these studies could accelerate market adoption and partnership opportunities. HeartBeam's progress also highlights the growing trend toward remote patient monitoring and the importance of accessible cardiac diagnostics.
For more information on HeartBeam's technology and cleared indications for use, visit HeartBeam's indications page. The full press release is available at this link.
